Media Coverage

Cleveland-based University Hospitals has completed the sale of select assets of its outreach laboratory services business to Quest Diagnostics. Under the agreement, Quest's labs in Twinsburg, Ohio, and Pittsburgh will handle testing for UH providers and patients who use Quest's lab services, according to a Jan. 27 news release. UH will continue to offer inpatient and select outpatient testing through its hospital-based labs. UH and Quest announced a definitive agreement in August.

Quest Diagnostics named Adrienne Brott its SVP and chief quality and regulatory affairs officer. She will oversee the firm's quality and regulatory strategy, as well as its efforts complying with US and global regulations and industry standards.

Meghan W. Starolis, MS, PhD, HCLD(ABB), Senior Science Director of Infectious Disease at Quest Diagnostics, explains how can laboratory professionals can ensure they are staying on top of testing, diagnosis, and treatment for respiratory illnesses that are growing in prevalence even before the traditional ‘cold and flu’ season.

Mainz Biomed has announced that it has made an agreement with Quest Diagnostics in which Quest will support the commercialization of Mainz Biomed's next-generation ColoAlert colorectal cancer (CRC) screening test. Under the terms of the agreement, Quest will provide clinical trial laboratory services for Mainz Biomeds’ ReconAAsense study, a prospective clinical study that includes approximately 15,000 subjects from 150 sites across the U.S. intended to provide data in support of the test’s submission for U.S. Food and Drug Administration (FDA) approval, Mainz said in a statement.

If you’ve had any medical tests over the past few decades, chances are you have encountered Quest Diagnostics. The Secaucus-based laboratory testing company boasts that it serves one-third of all Americans and works with half of the physicians and hospitals around the country.